Urothelial Carcinoma Diagnostics Market, By Test Type (Urine Cytology, Cystoscopy, Immunoassays, Fluorescence In Situ Hybridization (FISH), Biomarker Tests, and PCR-Based Tests), By Cancer Type, By End-user, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4226
|
Published Date
July 2025
|
Pages
355
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Urothelial Carcinoma Diagnostics Market size was valued at US$ 1,987.76 Million in 2024, expanding at a CAGR of 9.8% from 2025 to 2032.
The Urothelial Carcinoma Diagnostics Market encompasses the tools, tests, and technologies used for the detection and monitoring of urothelial carcinoma—a common form of bladder cancer that affects the lining of the urinary tract. Key diagnostic methods in this market include urine cytology, cystoscopy, imaging techniques such as CT and MRI, and molecular tests like fluorescence in situ hybridization (FISH) and NMP22 protein assays. Early detection is crucial, as it significantly improves treatment outcomes and helps reduce the risk of disease progression. Market growth is driven by the rising incidence of bladder cancer, increased public awareness, and a growing preference for non-invasive diagnostic methods.
Technological advancements, including liquid biopsy and biomarker-based tests, are further accelerating market expansion. Major end-users include hospitals, diagnostic laboratories, and research institutions. Geographically, North America leads the market, supported by a well-developed healthcare infrastructure and high diagnostic adoption rates. Regulatory approvals, along with continuous innovation aimed at improving test sensitivity and specificity, are shaping the evolving landscape of this dynamic market.
Urothelial Carcinoma Diagnostics Market- Market Dynamics
Growing awareness of sustainable development is expected to drive market demand.
A key niche driver of the Urothelial Carcinoma Diagnostics Market is the growing adoption of urinary biomarkers for early and non-invasive detection of bladder cancer. Traditional diagnostic methods, such as cystoscopy, are invasive, often uncomfortable for patients, and can be expensive. In contrast, urinary biomarkers present a less invasive, more patient-friendly alternative, capable of detecting genetic mutations, protein levels, and other molecular changes in urine that are indicative of urothelial carcinoma. Tests such as NMP22, UroVysion (FISH), and bladder tumor antigen (BTA) are increasingly being integrated into clinical practice for both initial diagnosis and ongoing surveillance. These tests offer greater convenience, support repeat testing, and in many cases, reduce the need for invasive procedures—especially important for patients requiring frequent monitoring due to the high recurrence rate of bladder cancer.
According to the World Health Organization (WHO), bladder cancer ranks among the top 10 most common cancers globally, with over 570,000 new cases and more than 200,000 deaths reported annually. In response, governments and public health agencies around the world are investing in early cancer detection programs, national cancer registries, and reimbursement policies for non-invasive diagnostic testing. For instance, initiatives like the U.S. Cancer Moonshot and Europe’s Beating Cancer Plan are promoting the development and adoption of innovative diagnostic technologies, including biomarker-based screening tools.
Moreover, advancements in genomics and proteomics are driving the discovery of next-generation urinary biomarkers with enhanced sensitivity and specificity. These innovations are improving diagnostic accuracy and are becoming essential tools for early-stage cancer detection. As precision medicine continues to gain traction, healthcare providers are actively seeking reliable, cost-effective diagnostic solutions. This trend is accelerating the shift toward urine-based biomarker testing, particularly in outpatient settings and regions with limited healthcare resources. The growing preference for non-invasive diagnostics—supported by global health initiatives—is poised to significantly shape the future landscape of urothelial carcinoma detection and management.
Urothelial Carcinoma Diagnostics Market- Segmentation Analysis:
The Global Urothelial Carcinoma Diagnostics Market is segmented on the basis of Test Type, Cancer Type, End-user, and Region.
The Urothelial Carcinoma Diagnostics Market is segmented into several test types, including Urine Cytology, Cystoscopy, Immunoassays, Fluorescence in Situ Hybridization (FISH), Biomarker Tests, PCR-Based Tests, and others. Among these, cystoscopy holds the most dominant position. Regarded as the gold standard for diagnosing and monitoring bladder cancer, cystoscopy allows for direct visualization of the bladder lining and enables biopsy and immediate therapeutic intervention when abnormalities are found. Although it is an invasive procedure, its high diagnostic accuracy and ability to detect recurrent or high-risk tumors make it the preferred choice among clinicians. Its widespread availability in hospitals and urology clinics, along with well-established clinical guidelines recommending its use, further reinforces its dominance in the diagnostics landscape. The continued reliance on cystoscopy for both initial diagnosis and routine follow-up, particularly in high-risk patients, underscores its critical role in urothelial carcinoma management.
Based on cancer type, the market is categorized into Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC). NMIBC represents the most dominant segment, as it accounts for approximately 75–80% of bladder cancer cases at the time of initial diagnosis. This form of cancer is characterized by a high recurrence rate, necessitating frequent and lifelong monitoring. As a result, patients with NMIBC undergo repeated diagnostic evaluations, including cystoscopy, urine cytology, and molecular tests, which drives demand for diagnostic tools in this segment. The need for long-term surveillance significantly contributes to the higher volume of diagnostic procedures, making NMIBC a key driver of market growth.
Globally, the burden of bladder cancer is considerable, with over 573,000 new cases and over 212,000 deaths reported annually, according to the World Health Organization (WHO). National health agencies and urology societies, such as the American Urological Association (AUA) and the European Association of Urology (EAU), recommend routine use of cystoscopy and urinalysis for the diagnosis and surveillance of urothelial carcinoma, especially NMIBC. Furthermore, public health programs in countries like the U.S., Germany, and Japan support early detection and frequent monitoring to manage recurrence and reduce mortality, thereby strengthening the demand for diagnostic tests—particularly cystoscopy—in the global urothelial carcinoma diagnostics market.
Urothelial Carcinoma Diagnostics Market- Geographical Insights
The North American urothelial carcinoma diagnostics market is defined by its advanced healthcare infrastructure, high cancer screening rates, and rapid adoption of innovative diagnostic technologies. The United States leads the region due to a high prevalence of bladder cancer, robust reimbursement frameworks, and strong research funding for oncology diagnostics. Regulatory support from agencies like the U.S. Food and Drug Administration (FDA) facilitates the accelerated approval and commercialization of cutting-edge biomarker-based and molecular diagnostic tests. Canada also contributes significantly to the regional landscape, driven by growing public awareness and government initiatives that emphasize early cancer detection and non-invasive diagnostic solutions. For instance, Canada’s national Cancer Strategy promotes improved access to early screening tools, while the U.S. government’s Cancer Moonshot Initiative aims to reduce cancer mortality by accelerating innovation in diagnostics and treatments.
Globally, government efforts to combat cancer are expanding, with organizations such as the World Health Organization (WHO) highlighting that over 570,000 new cases of bladder cancer are diagnosed annually. In response, numerous countries are prioritizing early detection through public health campaigns, funding for biomarker research, and regulatory reforms that encourage rapid development and deployment of diagnostic technologies. North America, with its concentration of diagnostic laboratories, precision medicine programs, and public-private research collaborations, continues to serve as a leading hub for advancements in urothelial carcinoma diagnostics, shaping trends that influence global markets.
Urothelial Carcinoma Diagnostics Market- Competitive Landscape:
The competitive landscape of the Urothelial Carcinoma Diagnostics Market is shaped by a mix of established diagnostic industry leaders and innovative biotechnology firms. Major players such as Roche Diagnostics, Abbott, and Thermo Fisher Scientific maintain a dominant position through their comprehensive diagnostic portfolios, global end-user networks, and significant investments in research and development. These companies offer advanced molecular and immunoassay-based testing solutions, often integrated with digital pathology platforms and laboratory automation systems—giving them a strategic advantage within large healthcare networks and hospitals. On the other hand, specialized biotech firms such as Myriad Genetics, Natera, and Biocept are driving innovation by focusing on precision diagnostics, particularly in the areas of liquid biopsy, genomic profiling, and urinary biomarkers for bladder cancer. These companies are leveraging advancements in next-generation sequencing (NGS) and artificial intelligence (AI) to enhance diagnostic sensitivity and specificity. Their technologies cater to the growing demand for non-invasive, accurate, and patient-centric diagnostic options, particularly for high-risk patients and those requiring frequent monitoring due to bladder cancer’s high recurrence rate.
Recent Developments:
- In June 2024, ALX Oncology Holdings Inc. presented data from its Phase 1 ASPEN-07 clinical trial (abstract #4575) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial represents the first report of evorpacept used in combination with the antibody-drug conjugate PADCEV (enfortumab vedotin) in patients with locally advanced or metastatic urothelial carcinoma, as part of an ongoing open-label, single-arm study.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Roche Diagnostics
- Abbott Laboratories
- Thermo Fisher Scientific
- Qiagen
- Bio-Rad Laboratories
- Illumina, Inc.
- Hologic, Inc.
- Agilent Technologies
- Myriad Genetics
- Danaher Corporation
- Siemens Healthineers
- Sysmex Corporation
- Becton, Dickinson and Company (BD)
- Genomic Health
- Epigenomics AG
- Bio-Techne Corporation
- Natera, Inc.
- Guardant Health
- Exact Sciences Corporation
- Biocept, Inc.
GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032
- Urine Cytology
- Cystoscopy
- Immunoassays
- Fluorescence In Situ Hybridization (FISH)
- Biomarker Tests
- PCR-Based Tests
- Others
GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Muscle Invasive Bladder Cancer (MIBC)
GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Diagnostic Laboratories
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Academic & Research Centers
GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Urothelial Carcinoma Diagnostics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Urothelial Carcinoma Diagnostics Market Snippet by Test Type
2.1.2. Urothelial Carcinoma Diagnostics Market Snippet by Cancer Type
2.1.3. Urothelial Carcinoma Diagnostics Market Snippet by End-user
2.1.4. Urothelial Carcinoma Diagnostics Market Snippet by Country
2.1.5. Urothelial Carcinoma Diagnostics Market Snippet by Region
2.2. Competitive Insights
3. Urothelial Carcinoma Diagnostics Key Market Trends
3.1. Urothelial Carcinoma Diagnostics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Urothelial Carcinoma Diagnostics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Urothelial Carcinoma Diagnostics Market Opportunities
3.4. Urothelial Carcinoma Diagnostics Market Future Trends
4. Urothelial Carcinoma Diagnostics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Urothelial Carcinoma Diagnostics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Urothelial Carcinoma Diagnostics Market Landscape
6.1. Urothelial Carcinoma Diagnostics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Urothelial Carcinoma Diagnostics Market – By Test Type
7.1. Overview
7.1.1. Segment Share Analysis, By Test Type, 2024 & 2032 (%)
7.1.2. Urine Cytology
7.1.3. Cystoscopy
7.1.4. Immunoassays
7.1.5. Fluorescence In Situ Hybridization (FISH)
7.1.6. Biomarker Tests
7.1.7. PCR-Based Tests
7.1.8. Others
8. Urothelial Carcinoma Diagnostics Market – By Cancer Type
8.1. Overview
8.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
8.1.2. Non-Muscle Invasive Bladder Cancer (NMIBC)
8.1.3. Muscle Invasive Bladder Cancer (MIBC)
9. Urothelial Carcinoma Diagnostics Market – By End-user
9.1. Overview
9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
9.1.2. Hospitals
9.1.3. Diagnostic Laboratories
9.1.4. Cancer Research Institutes
9.1.5. Ambulatory Surgical Centers
9.1.6. Academics & Research Centers
10. Urothelial Carcinoma Diagnostics Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Urothelial Carcinoma Diagnostics Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Urothelial Carcinoma Diagnostics Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Roche Diagnostics
11.2.2. Abbott Laboratories
11.2.3. Thermo Fisher Scientific
11.2.4. Qiagen
11.2.5. Bio-Rad Laboratories
11.2.6. Illumina, Inc.
11.2.7. Hologic, Inc.
11.2.8. Agilent Technologies
11.2.9. Myriad Genetics
11.2.10. Danaher Corporation
11.2.11. Siemens Healthineers
11.2.12. Sysmex Corporation
11.2.13. Becton, Dickinson and Company (BD)
11.2.14. Genomic Health
11.2.15. Epigenomics AG
11.2.16. Bio-Techne Corporation
11.2.17. Natera, Inc.
11.2.18. Guardant Health
11.2.19. Exact Sciences Corporation
11.2.20. Biocept, Inc.
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
